Antoniel Augusto Severo Gomes

Antoniel Augusto Severo Gomes

Auto-generated profile, based on publicly available information

Antoniel Augusto Severo Gomes

Laboratory of Molecular Neuropharmacology and Bioinformatics, Unitat de Bioestadística and Institut de Neurociències

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
NDNatalina Dantas
Natalina Dantas
TAThiago Aquino
Thiago Aquino
JAJoão Xavier de Araújo-Júnior
João Xavier de Araújo-Júnior
Edeíldo Ferreira da Silva-JúniorEdeíldo Ferreira da Silva-Júnior
Edeíldo Ferreira da Silva-Júnior
EGEdnaldo Almeida Gomes
Ednaldo Almeida Gomes
Francisco Mendonça JuniorFrancisco Mendonça Junior
Francisco Mendonça Junior

9 July 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
GSGuilherme Henrique Marchi Salvador
Guilherme Henrique Marchi Salvador
TDThiago R. Dreyer
Thiago R. Dreyer
AGAntoniel A. S. Gomes
Antoniel A. S. Gomes
WCWalter L. G. Cavalcante
Walter L. G. Cavalcante
JSJuliana I. dos Santos
Juliana I. dos Santos
MFMarcos R M Fontes
Marcos R M Fontes
Local myonecrosis is the main event resulting from snakebite envenomation by theBothropsgenus and, frequently, it is not efficiently neutralized by antivenom administration. Proteases, phospholipases A2(PLA2) and PLA2-like toxins are found in venom related to muscle damage. Functional sites responsible for PLA2-like toxins activity have been proposed recently; they consist of a membrane docking-site and a membrane rupture-site. Herein, a combination of functional, biophysical and crystallographic techniques was used to characterize the interaction between suramin and MjTX-I (a PLA2-like toxin fromBothrops moojenivenom). Functionalin vitroneuromuscular assays were performed to study the biological effects of the protein-ligand interaction, demonstrating that suramin neutralizes the myotoxic effect of MjTX-I. Calorimetric assays showed two different binding events:(i)inhibitor-protein interactions and(ii)toxin oligomerization processes. These hypotheses were also corroborated with dynamic light and small angle X-ray scattering assays. The crystal structure of the MjTX-I/suramin showed a totally different interaction mode compared to other PLA2-like/suramin complexes. Thus, we suggested a novel myotoxic mechanism for MjTX-I that may be inhibited by suramin. These results can further contribute to the search for inhibitors that will efficiently counteract local myonecrosis in order to be used as an adjuvant of conventional serum therapy.

24 January 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
GSGuilherme Henrique Marchi Salvador
Guilherme Henrique Marchi Salvador
FCFábio Florença Cardoso
Fábio Florença Cardoso
AGAntoniel A. Gomes
Antoniel A. Gomes
WCWalter L. G. Cavalcante
Walter L. G. Cavalcante
MGMárcia Gallacci
Márcia Gallacci
MFMarcos R M Fontes
Marcos R M Fontes
Ophidian accidents are considered an important neglected tropical disease by the World Health Organization. Particularly in Latin America,Bothropssnakes are responsible for the majority of the snakebite envenomings that are not efficiently treated by conventional serum therapy. Thus, the search for simple and efficient inhibitors to complement this therapy is a promising research area, and a combination of functional and structural assays have been used to test candidate ligands against specific ophidian venom compounds. Herein, we tested a commercial drug (acetylsalicylic acid, ASA) and a plant compound with antiophidian properties (rosmarinic acid, RA) using myographic, crystallographic and bioinformatics experiments with a phospholipase A2-like toxin, MjTX-II. MjTX-II/RA and MjTX-II/ASA crystal structures were solved at high resolution and revealed the presence of ligands bound to different regions of the toxin. However,in vitromyographic assays showed that only RA is able to prevent the myotoxic effects of MjTX-II. In agreement with functional results, molecular dynamics simulations showed that the RA molecule remains tightly bound to the toxin throughout the calculations, whereas ASA molecules tend to dissociate. This approach aids the design of effective inhibitors of PLA2-like toxins and, eventually, may complement serum therapy.

1 January 2022 in Trends in Parasitology
Verified
Journal Article
Closed access
STSamuel Cota Teixeira
Samuel Cota Teixeira
Marcelo Santos da SilvaMarcelo Santos da Silva
Marcelo Santos da Silva
AGAntoniel Augusto Severo Gomes
Antoniel Augusto Severo Gomes
Nilmar MorettiNilmar Moretti
Nilmar Moretti
DLDAIANA LOPES
DAIANA LOPES
VRVeridiana Rodrigues
Veridiana Rodrigues

1 September 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AGAntoniel A. S. Gomes
Antoniel A. S. Gomes
NSNatália C. M. Santos
Natália C. M. Santos
LRLeonardo R. Rosa
Leonardo R. Rosa
RBRafael J. Borges
Rafael J. Borges
MFMarcos R. M. Fontes
Marcos R. M. Fontes
ESErick J.R. Silva
Erick J.R. Silva
Novel male contraceptives will promote gender equality in sharing contraceptive responsibility. The sperm-associated protein epididymal protease inhibitor (EPPIN) is a promising target for non-hormonal male contraception. EPPIN interacts with the semen coagulum protein semenogelin-1 (SEMG1) on the sperm surface, leading to transient inhibition of sperm motility after ejaculation. Small organic molecules targeting EPPIN's SEMG1-binding are under development as male contraceptives. Here, we combined computational approaches to uncover key aspects underlying EPPIN binding to SEMG1 and small organic ligands. We generated a human EPPIN model showing a typical arrangement of the WFDC (Whey-acid four disulfide core)-type and Kunitz-type domains, connected by a hinge region. Determining the EPPIN model's intrinsic motion by molecular dynamics simulations and normal mode analysis revealed a conformation, presenting a binding pocket that accommodates SEMG1Glu229-Gln247, EP055, and EP012. EPPIN's residues Phe63 and Lys68 (WFDC domain), Asp71 (hinge region), and Asn113, Asn114, and Asn115 (Kunitz domain) were identified as hot spots for SEMG1, EP055, and EP012 binding. Moreover, hydrophobic and hydrophilic residues in the WFDC and Kunitz domains allow plasma membrane anchoring, orienting the EPPIN binding pocket to the solvent. Targeting EPPIN's essential residues for its biomolecular interactions may improve the rational design of EPPIN ligands as spermiostatic compounds.

6 May 2025 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
AGAntoniel A. S. Gomes
Antoniel A. S. Gomes
Jesús GiraldoJesús Giraldo
Jesús Giraldo
The μ-opioid receptor (μOR) is a class A G Protein-Coupled Receptor (GPCR) targeted by natural and synthetic ligands to provide analgesia to patients with pain of various etiologies. Available opioid medications present several unwanted side effects, stressing the need for safer pain therapies. Despite the attractive proposal that biasing μOR signaling toward G protein pathways would lead to fewer side effects, recent studies indicate that low-efficacy opioid drugs, such as buprenorphine, may represent a safer alternative. In the present work, we combine molecular docking, microsecond-time scale molecular dynamics (MD) simulations, and metadynamics to investigate the conformational dynamics of the μOR bound to morphine or buprenorphine. Our objective was to determine structural aspects associated with the unique pharmacological effects caused by the latter, taking morphine as a reference. MD simulations identified a salt bridge with D1493.32 as crucial for stabilizing both ligands into the μOR orthosteric site, with this interaction being weaker in buprenorphine. The morphinan-scaffold of both ligands shared contacts with transmembrane (TM) helix residues of the receptor, including TM3, TM5, TM6, and TM7. Conversely, while morphine showed stronger interactions with a few TM3 residues, additional chemical groups of buprenorphine showed stronger interactions with TM2, extracellular loop 2 (ECL2), and TM7 residues. We also observed distinct TM arrangements induced by these ligands, with buprenorphine causing an extracellular outward movement of TM7 and morphine provoking intracellular inward movements of TM5 and TM7 of the receptor. In addition, we found that buprenorphine tends to explore deeper regions in the μOR orthosteric site, further supported by funnel-metadynamics, resulting in diverse side chain orientations of W2956.48. Metadynamics also unveiled distinct intermediate states for morphine and buprenorphine, with the latter accessing a secondary binding site associated with partial μOR agonists. Our results indicate that the weakened salt bridge of buprenorphine with D1493.32, along with the strong TM7 interaction through its cyclopropyl group, may explain its low efficacy and consequent partial μOR agonism. Furthermore, ECL2 interactions may contribute to explaining the biased agonism of buprenorphine, a common feature shared with other opioid modulators with similar functional effects. Our study sheds light on the complex pharmacology of buprenorphine, identifying structural aspects associated with its partial and biased μOR agonism. These results can provide valuable information for the design of new effective and safer opioid drugs.